Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Based imaging aims to spot prostate cancer left behind after surgery

NCT ID NCT07826858

Diagnosis Sponsor: Massimo Valerio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

After surgery to remove prostate cancer, cancer cells sometimes remain at the edge of the removed tissue, which can lead to the cancer returning. Researchers are testing a light-based imaging method called hyperspectral imaging to examine the removed prostate and identify cancer at the margins. The study enrolls 26 men with localized prostate cancer and compares the imaging results with standard pathology to see if the technique can accurately map tumor extent.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperspectral imaging of removed prostate tissue
What this could lead to
If it works, hyperspectral imaging could give surgeons a faster way to check prostate margins during surgery, potentially reducing the need for repeat operations.
What could go wrong
This is a small, early feasibility study of 26 men. The imaging may not match pathology accurately, and results may not apply to other hospitals or surgeons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 26 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histological diagnosis (biopsy) of Pca * Prostate volume \< 100 cm3 (measured on preoperative MRI) for a smooth acquisition with the hyperspectral device * Capable of forming his own views Exclusion Criteria: * Unwilling to participate. * Inability to follow study procedures, for example due to language problems, psychological disorders, dementia, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperspectral imaging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Margins of Excision prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperspectral imaging Localized prostate cancer Positive surgical margin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Genève - Dept de Chirurgie - Service d'Urologie

    RECRUITING

    Geneva, Canton of Geneva, 1205, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.